Biophytis: Capital Increase of €5.3M for OBA Trial
The Parisian biotech company issued its new shares at a unit price of €0.052, representing a 24.1% discount compared to the weighted average price over the ten trading sessions preceding the price-setting, for the benefit of institutional investors. The transaction brings the number of shares in circulation to 350,132,497: a shareholder holding 1% of capital before the operation without participating in it holds 0.71%, and 0.57% if all subscription warrants are exercised.
Financing Dedicated to Phase 2 Trial in Obesity
Biophytis announced on September 11, 2026 the completion of a capital increase with a gross amount of €5.3M, of which €4.75M in cash and €0.55M in debt repayment in Hexagon shares. The operation is based on the issuance of 101,923,092 new shares accompanied by subscription warrants entitling holders to 127,403,865 additional shares. The proceeds are intended for the continuation of the OBA clinical trial in obesity in the United States, European Union and Brazil, as well as for covering operating expenses and current charges of the company. According to the company, the combination of the transaction proceeds and existing credit lines enables full financing of the trial until the publication of initial results, expected in the first half of 2028. The placement is distributed between American institutional investors (62%) and European investors (38%).
BIO101 Developed in Obesity and Sarcopenia
The OBA program aims to evaluate BIO101 as a potential complement to GLP-1 receptor agonist treatments, with the objective of preserving muscle strength and mobility during weight loss. The launch of the phase 2 trial is scheduled for the first quarter of 2027. In parallel, the company indicates it is continuing BIO101 development in sarcopenia, preparing the SARA-31 phase 3 study and deploying its joint venture in Hong Kong. Stanislas Veillet, Chief Executive Officer, stated that this financing enables the obesity trial to move from the regulatory and operational preparation phase to clinical execution. Following the placement, the company has cash and cash equivalents of €8.9M, with a cash runway extended at least until the first quarter of 2028.
